IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the claims:

Claim 1 (**currently amended**): A quinazoline derivative of the Formula I



I

wherein

Z is an O, S, SO, SO_2, $N(R^2)$ or $C(R^2)_2$ group, wherein each R^2 group, which may be the same or different, is hydrogen or (1-6C)alkyl;

m is 1 or 2 ~~0, 1, 2, 3 or 4~~;

each R^1 group, which may be the same or different, is selected from halogeno, trifluoromethyl, hydroxy, amino, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, or from a group of the formula :

$$Q^1\text{-}X^1\text{-}$$

wherein X^1 is a direct bond or is O and Q^1 is heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R^1 substituent are optionally separated by the insertion into the chain of an O,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more halogeno groups or a group selected from amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxyalkylamino di-[(1-6C)alkoxyalkyl]amino or hydroxy(1-6C)alkylamino,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, halogeno(1-6C) alkyl, (1-6C)alkyl, (1-6C)alkoxy, formyl, (2-6C)alkanoyl, hydroxy and hydroxy(1-6C)alkyl,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo substituents;

~~**each R^1 group**, which may be the same or different, is selected from halogeno, trifluoromethyl, cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :~~

~~Q^1-X^1-~~

~~wherein X^1 is a direct bond or is selected from O, S, SO, SO_2, $N(R^4)$, CO, $CH(OR^4)$, $CON(R^4)$, $N(R^4)CO$, $SO_2N(R^4)$, $N(R^4)SO_2$, $OC(R^4)_2$, $SC(R^4)_2$ and $N(R^4)C(R^4)_2$, wherein R^4 is hydrogen or (1-6C)alkyl, and Q^1 is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl, or $(R^+)_m$ is (1-3C)alkylenedioxy, and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R^1 substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO_2, $N(R^5)$, CO, $CH(OR^5)$, $CON(R^5)$, $N(R^5)CO$, $SO_2N(R^5)$, $N(R^5)SO_2$, CH=CH and C≡C wherein R^5 is hydrogen or (1-6C)alkyl or, when the inserted group is $N(R^5)$, R^5 may also be (2-6C)alkanoyl,~~

~~and wherein any CH_2=CH- or HC≡C- group within a R^1 substituent optionally bears at the terminal CH_2= or HC≡ position a substituent selected from halogeno, carboxy, carbamoyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl or from a group of the formula :~~

~~Q^2-X^2-~~

~~wherein X^2 is a direct bond or is selected from CO and N(R^6)CO, wherein R^6 is hydrogen or (1-6C)alkyl, and Q^2 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,~~

~~and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxyalkylamino di-[(1-6C)alkoxyalkyl]amino or hydroxy(1-6C)alkylamino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :~~

~~-X^3-Q^3~~

~~wherein X^3 is a direct bond or is selected from O, S, SO, SO_2, N(R^7), CO, CH(OR^7), CON(R^7), N(R^7)CO, SO_2N(R^7), N(R^7)SO_2, C(R^7)$_2$O, C(R^7)$_2$S and N(R^7)C(R^7)$_2$, wherein R^7 is hydrogen or (1-6C)alkyl, and Q^3 is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,~~

~~and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, formyl, (1-~~

~~6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :~~

$$-X^4-R^8$$

~~wherein X^4 is a direct bond or is selected from O and $N(R^9)$, wherein R^9 is hydrogen or (1-6C)alkyl, and R^8 is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, or a group of the formula :~~

$$-X^5-Q^4$$

~~wherein X^5 is a direct bond or is selected from O, $N(R^{10})$ and CO, wherein R^{10} is hydrogen or (1-6C)alkyl, and Q^4 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy,~~

~~and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo or thioxo substituents;~~

n is 0, 1 or 2; and

R^3 is selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-

6C)alkynoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :

$$-X^6-R^{11}$$

wherein X^6 is a direct bond or is selected from O and $N(R^{12})$, wherein R^{12} is hydrogen or (1-6C)alkyl, and R^{11} is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl or di-[(1-6C)alkyl]amino-(1-6C)alkyl;

$\mathbf{Z^2}$ is a C≡C or $C(R^{13})=C(R^{13})$ group, wherein each R^{13} group, which may be the same or different, is hydrogen or (1-6C)alkyl; and

R^{14} is selected from hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, from a group of formula:

$$(CH_2)_x\text{-}N(R^c)\text{-}C(O)\text{-}NR^aR^b$$

wherein x is 0, 1, 2 or 3, R^c is hydrogen or (1-6C)alkyl and R^a and R^b are each independently selected from hydrogen and (1-6C)alkyl or R^a and R^b together with the nitrogen to which they are attached form morpholino

or from a group of the formula :

$$-X^7-Q^5$$

wherein X^7 is a direct bond and Q^5 is aryl, heteroaryl, heterocyclyl, heterocyclyl-(1-6C)alkyl or heterocyclyloxy-(1-6C)alkyl,

and wherein any CH, CH_2 or CH_3 group within a R^{14} substituent optionally bears on each said CH, CH_2 or CH_3 group one or more halogeno, (1-6C)alkyl, (1-6C)alkoxy, carbamoyl, (1-6C)alkoxy, N-(1-6C)alkylcarbamoyl, N, N-di-[(1-6C)alkyl]carbamoyl or from a group of the formula :

$$-X^8-Q^6$$

wherein X^8 is a direct bond or O and Q^6 is aryl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, cycloalkyl or heterocyclyl group within a substituent on R^{14} optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, hydroxyl, amino, (1-6C)alkyl or (1-6C)alkanoyl,

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 or 2 oxo or thioxo substituents;

~~R^{14} is selected from halogeno, cyano, isocyano, formyl, carboxy, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, from a group of formula:~~

~~$(CH_2)_x N(R^c) C(O) NR^a R^b$~~

~~wherein x is 0, 1, 2 or 3, R^c is hydrogen or (1-6C)alkyl and R^a and R^b are each independently selected from hydrogen and (1-6C)alkyl or R^a and R^b together with the nitrogen to which they are attached form a 4 to 7 membered heterocyclyl optionally containing up to two further heteratoms selected from oxygen, nitrogen or sulphur,~~

~~or from a group of the formula :~~

~~$=X^7=Q^5$~~

~~wherein X^7 is a direct bond or is selected from CO, $CH(OR^{15})$, $CON(R^{15})$ or $SO_2N(R^{15})$, wherein R^{15} is hydrogen or (1-6C)alkyl, and Q^5 is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl, heterocyclyl-(1-6C)alkyl or heterocyclyloxy-(1-6C)alkyl,~~

~~and wherein any CH, CH_2 or CH_3 group within a R^{14} substituent optionally bears on each said CH, CH_2 or CH_3 group one or more halogeno, (1-6C)alkyl or (3-6C)cycloalkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-~~

6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :

$$-X^8-Q^6$$

wherein X^8 is a direct bond or is selected from O, S, SO, SO_2, $N(R^{16})$, CO, $CH(OR^{16})$, $CON(R^{16})$, $N(R^{16})CO$, $SO_2N(R^{16})$, $N(R^{16})SO_2$, $C(R^{16})_2O$, $C(R^{16})_2S$ and $N(R^{16})C(R^{16})_2$, wherein R^{16} is hydrogen or (1-6C)alkyl, and Q^6 is aryl, aryl-(1-6C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, heteroaryl or heterocyclyl group within a substituent on R^{14} optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl, (1-6C)alkanesulphonylamino, N-(1-6C)alkyl-(1-6C)alkanesulphonylamino or from a group of the formula :

$$-X^9-R^{17}$$

wherein X^9 is a direct bond or is selected from O and $N(R^{18})$, wherein R^{18} is hydrogen or (1-6C)alkyl, and R^{17} is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl,

or from a group of the formula :

$$-X^{10}-Q^7$$

~~wherein X^{10} is a direct bond or is selected from O, $N(R^{19})$ and CO, wherein R^{19} is hydrogen or (1-6C)alkyl, and Q^7 is aryl, aryl-(1-6C)alkyl, heteroaryl, heteroaryl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl which optionally bears 1 or 2 substituents, which may be the same or different, selected from halogeno, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl and (1-6C)alkoxy,~~

~~and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 or 2 oxo or thioxo substituents;~~

or a pharmaceutically-acceptable salt thereof.

Claim 2 (**cancelled**)

Claim 3 (**currently amended**): The ~~A~~ quinazoline derivative of the Formula I according to claim 1 wherein

Z is O or NH

m is 1 and the $\mathbf{R^1}$ group is located at the 5-, 6-, or 7-position or m is 2 and each R^1 group, which may be the same or different, is located at the 5- and 7-positions or at the 6- and 7-positions and R^1 is selected from methoxy, ethoxy, propoxy, isopropoxy, 2-methylpropoxy, or from a group of the formula :

$$Q^1\text{-}X^1\text{-}$$

wherein X^1 is O and Q^1 is piperidino, piperidin-3-yl, piperidin-4-yl, 1-, 3- or 4-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl, 1-, 2- or 3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 3- or 4-piperidinylmethyl, 1-, 3- or 4-homopiperidinylmethyl, 2-pyrrolidin-1-ylethyl, 3-pyrrolidin-2-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, tetrahydro-2H-pyran-4-yl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, piperidin-4-ylmethyl, 2-piperidin-3-ylethyl, 3-piperidin-1-ylpropyl, 3-piperidin-3-ylpropyl, 2-piperidin-4-ylethyl, 3-piperidin-4-ylpropyl, 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-

ylpropyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, 4-piperazin-1-ylbutyl, 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl,

and wherein adjacent carbon atoms in any (2-6C)alkylene chain within a R^1 substituent are optionally separated by the insertion into the chain of a O,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more fluoro, chloro or bromo groups or a substituent selected from amino, methylamino, dimethylamino, methoxyethylamino, di-(methoxyethyl)amino, or hydroxypropylamino,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from methyl, ethyl, methoxy, ethoxy, formyl, acetyl, hydroxyl, hydroxymethyl, fluoroethyl or hydroxypropylamino,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo substituents;

n is 0 or 1 and $\mathbf{R^3}$ group, if present, is located at the 5- or 6-position of the 1,3-benzodioxol-4-yl group and is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, methoxy and ethoxy;

$\mathbf{Z^2}$ is a C≡C or CH=CH group; and

$\mathbf{R^{14}}$ is selected from hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, from a group of formula:

$$(CH_2)_x\text{-}N(R^c)\text{-}C(O)\text{-}NR^aR^b$$

wherein x is 0, 1, 2 or 3, R^c is hydrogen or (1-6C)alkyl and R^a and R^b are each independently selected from hydrogen and (1-6C)alkyl or R^a and R^b together with the nitrogen to which they are attached form morpholino

or from a group of the formula :

$$-X^7-Q^5$$

wherein X^7 is a direct bond and Q^5 is aryl, heteroaryl, heterocyclyl, heterocyclyl-(1-6C)alkyl or heterocyclyloxy-(1-6C)alkyl,

and wherein any CH, CH_2 or CH_3 group within a R^{14} substituent optionally bears on each said CH, CH_2 or CH_3 group one or more halogeno, (1-6C)alkyl, (1-6C)alkoxy,

carbamoyl, (1-6C)alkoxy, N-(1-6C)alkylcarbamoyl, N, N-di-[(1-6C)alkyl]carbamoyl or from a group of the formula :

$$-X^8-Q^6$$

wherein X^8 is a direct bond or O and Q^6 is aryl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,

and wherein any aryl, cycloalkyl or heterocyclyl group within a substituent on R^{14} optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from halogeno, hydroxyl, amino, (1-6C)alkyl or (1-6C)alkanoyl,

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 or 2 oxo or thioxo substituents;

or a pharmaceutically acceptable acid addition salt thereof.

Claim 4 (**currently amended**): The ~~A~~ quinazoline derivative of the Formula I, or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R^1, R^2, R^3, R^{14}, Z^2, m and n have any of the meanings defined in claim 1 and Z is NH.

Claim 5 (**currently amended**): The ~~A~~ quinazoline derivative of the Formula I according to claim 1 wherein

Z is NH

m is 2, and the **first R^1** group is a 6-methoxy group and the **second R^1** group is located at the 7-position and is selected from methoxy, 2-methoxyethoxy, 2-fluoroethoxy, 3-chloroethoxy, isopropoxy, isopropylmethoxy, 3-dimethylaminopropoxy, 2-dimethylaminoethoxy, dimethylaminoisopropoxy, 2-[3-(hydroxy)propylamino]ethoxy, 3-[bis(2-methoxyethyl)amino]propoxy, 2-(2-methoxyethoxy)ethoxy, 3-chloropropoxy, 2-(2-chloroethoxy)ethoxy, 3-piperazin-1-ylpropoxy, 2-piperazin-1-ylethoxy, 4-piperazin-1-ylbutoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy, 4-(4-methylpiperazin-1-yl)butoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy, 4-[4-(2-fluoroethyl)piperazin-1-yl]butoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 2-(4-acetylpiperazin-1-yl)ethoxy, 4-(4-acetylpiperazin-1-yl)butoxy, 3-(4-formylpiperazin-1-yl)propoxy, 2-(4-formylpiperazin-1-yl)ethoxy, 4-(4-

formylpiperazin-1-yl)butoxy, 3-morpholinopropoxy, 2-morpholin-4-ylethoxy, 4-morpholin-4-ylbutoxy, 3-(2,6-dimethylmorpholin-4-yl)propoxy, 2-(2,6-dimethylmorpholin-4-yl)ethoxy, 4-(2,6-dimethylmorpholin-4-yl)butoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 3-[2-(hydroxymethyl)pyrrolidin-1-yl]propoxy, 4-[2-(hydroxymethyl)pyrrolidin-1-yl]butoxy, 2-[2-(hydroxymethyl)pyrrolidin-1-yl]ethoxy, 3-(4-hydroxypiperidin-1-yl)propoxy, 2-(4-hydroxypiperidin-1-yl)ethoxy, 4-(4-hydroxypiperidin-1-yl)butoxy, 1-methylpiperidin-4-ylmethoxy, 3-(1-methylpiperidin-4-yl)propoxy, 3-(4-methoxypiperidin-1-yl)propoxy, 3-(4-methoxypiperidin-1-yl)ethoxy or 4-(4-methoxypiperidin-1-yl)butoxy

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo substituents;

n is 0 or 1 and $\mathbf{R^3}$ group, if present, is located at the 5-position of the 1,3-benzodioxol-yl group and is selected from fluoro, chloro, bromo, trifluoromethyl, cyano, hydroxy, methyl, ethyl, methoxy and ethoxy;

$\mathbf{Z^2}$ is a C≡C or CH=CH group; and

$\mathbf{R^{14}}$ is selected from (1-6C)alkoxy-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, hydroxyl-(1-6C)alkyl or from a group of formula:

$$(CH_2)_x\text{-}N(R^c)\text{-}C(O)\text{-}NR^aR^b$$

wherein x is 0, 1, 2 or 3, R^c is hydrogen or (1-6C)alkyl and R^a and R^b are each independently selected from hydrogen and (1-6C)alkyl or R^a and R^b together with the nitrogen to which they are attached form morpholino,

or from a group of the formula :

$$-X^7-Q^5$$

wherein X^7 is a direct bond and Q^5 is aryl, heteroaryl, heterocyclyl, heterocyclyl-(1-6C)alkyl, or heterocyclyloxy-(1-6C)alkyl,

and wherein any CH, CH_2 or CH_3 group within a R^{14} substituent optionally bears on each said CH, CH_2 or CH_3 group a substituent selected from (1-6C)alkoxy, carbamoyl, N-(1-6C)alkylcarbamoyl or a group of the formula :

$$-X^8-Q^6$$

wherein X^8 is a direct bond or O and Q^6 is (3-7C)cycloalkyl or heterocyclyl and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 oxo substituent;

or a pharmaceutically acceptable acid addition salt thereof.

Claim 6 (**currently amended**): The ~~A~~ quinazoline derivative of the Formula I, or a pharmaceutically acceptable acid addition salt thereof, according to claim 1 wherein R^1, R^2 R^3, Z, Z^2, m and n have any of the meanings defined in claim 1 and R^{14} is a group of the formula:

$$(CH_2)_x\text{-}N(R^c)\text{-}C(O)\text{-}NR^aR^b$$

wherein x is 1, R^c is hydrogen or (1-3C) alkyl and R^a and R^b are each independently selected from hydrogen and (1-3C)alkyl.

Claim 7 (**currently amended**): The ~~A~~ quinazoline derivative of the Formula I according to claim 1 wherein

Z is NH

m is 2, and the **first R^1** group is a 6-methoxy group and the **second R^1** group is located at the 7-position and is selected from methoxy, 2-methoxyethoxy, isopropoxy, isopropylmethoxy, 3-dimethylaminopropoxy, dimethylaminoisopropoxy, 2-[3-(hydroxy)propylamino]ethoxy, 3-[bis(2-methoxyethyl)amino]propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(3-oxo-4-methylpiperazin-1-yl)propoxy, 3-(2-oxo-4-methylpiperazin-1-yl)propoxy, 3-morpholinopropoxy, 2-morpholin-4-ylethoxy, 4-morpholin-4-ylbutoxy, 3-(2,6-dimethylmorpholin-4-yl)propoxy, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propoxy, 2-fluoroethoxy, 3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 3-(4-formylpiperazin-1-yl)propoxy, 3-piperazin-1-ylpropoxy, 3-(4-hydroxypiperidin-1-yl)propoxy, 3-[2-(hydroxymethyl)pyrrolidin-1-yl]propoxy, 2-(2-methoxyethoxy)ethoxy, 3-chloropropoxy, 2-(2-chloroethoxy)ethoxy, 1-methylpiperidin-4-ylmethoxy, 3-(4-methoxypiperidin-1-yl)propoxy or 3-(4-hydroxypiperidin-1-yl)propoxy,

n is 1 and $\mathbf{R^3}$ group, if present, is located at the 6 position of the 1,3-benzodioxol group and is selected from fluoro, chloro or bromo;

$\mathbf{Z^2}$ is a C≡C or CH=CH group; and

$\mathbf{R^{14}}$ is selected from methoxymethyl, 1-methoxyethyl, 2-methoxyethyl, methoxyisopropyl, 2-methoxypropyl, ethoxymethyl, methoxyethoxymethyl, hydroxymethyl, carbamoylmethoxymethyl, methylcarbamoylmethoxymethyl, isopropoxymethyl, di-(methylamino)methyl, hydroxyisopropyl, (cyclopropylmethoxy)methyl, (cyclopentylmethoxy)methyl from a group of formula:

$$(CH_2)_x\text{-}N(R^c)\text{-}C(O)\text{-}NR^aR^b$$

wherein x is 1, R^c is hydrogen and R^a and R^b are each independently selected from hydrogen, and methyl or R^a and R^b together with the nitrogen to which they are attached form morpholino, or x is 1 and R^a, R^b and R^c are all methyl, or is selected from 2-oxo-pyrrolidin-1-ylmethyl, pyridin-2-yl, (tetrahydrofuran-3-ylmethoxy)methyl, (tetrahydrofuran-3-yloxy)methyl, [(1,3-dioxolan-2-yl)methoxy]methyl, phenyl, pyridin-3-yl, pyrazin-3-yl, pyrimidin-2-yl, 1H-pyrazol-4-yl or 1H-pyrazol-5-yl;

or a pharmaceutically acceptable acid addition salt thereof.

Claim 8 (**currently amended**): The ~~A~~ quinazoline derivative of the Formula I according to claim 1 wherein

Z is NH

m is 2 and each $\mathbf{R^1}$ group, which may be the same or different, is located at the 5- and 7-positions and R^1 is selected from methoxy, ethoxy, propoxy, isopropoxy, 2-methylpropoxy, vinyloxy, or from a group of the formula :

$$Q^1\text{-}X^1\text{-}$$

wherein X^1 is O and Q^1 is 1-, 2-, or 3-pyrrolidinyl, piperidino, piperidin-3-yl, piperidin-4-yl, 1-, 3- or 4-homopiperidinyl, piperazin-1-yl, homopiperazin-1-yl, 1-, 2- or 3-pyrrolidinylmethyl, morpholinomethyl, piperidinomethyl, 3- or 4-piperidinylmethyl, 1-, 3- or 4-homopiperidinylmethyl, 2-pyrrolidin-1-ylethyl, 3-

pyrrolidin-2-ylpropyl, pyrrolidin-2-ylmethyl, 2-pyrrolidin-2-ylethyl, 3-pyrrolidin-1-ylpropyl, 4-pyrrolidin-1-ylbutyl, 2-morpholinoethyl, 3-morpholinopropyl, 4-morpholinobutyl, tetrahydro-2H-pyran-4-yl, 2-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)ethyl, 3-(1,1-dioxotetrahydro-4H-1,4-thiazin-4-yl)propyl, 2-piperidinoethyl, 3-piperidinopropyl, 4-piperidinobutyl, 2-piperidin-3-ylethyl, piperidin-4-ylmethyl, 3-piperidin-1-ylpropyl, 3-piperidin-3-ylpropyl, 2-piperidin-4-ylethyl, 3-piperidin-4-ylpropyl, 2-homopiperidin-1-ylethyl, 3-homopiperidin-1-ylpropyl, 2-piperazin-1-ylethyl, 3-piperazin-1-ylpropyl, 4-piperazin-1-ylbutyl, 2-homopiperazin-1-ylethyl or 3-homopiperazin-1-ylpropyl,

and wherein any CH_2 or CH_3 group within a R^1 substituent optionally bears on each said CH_2 or CH_3 group one or more fluoro or chloro groups or a substituent selected from amino, methylamino, methoxy, dimethylamino, methoxyethylamino, di-(methoxyethyl)amino or hydroxypropylamino,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1, 2 or 3 substituents, which may be the same or different, selected from methyl, ethyl, methoxy, ethoxy, formyl, acetyl, hydroxyl, hydroxymethyl, fluoroethyl or hydroxypropylamino,

and wherein any heterocyclyl group within a substituent on R^1 optionally bears 1 or 2 oxo substituents;

n is 0 or 1 and $\mathbf{R^3}$ group, if present, is located at the 5 position of the 1,3-benzodioxol group and is selected from fluoro or chloro;

$\mathbf{Z^2}$ is a C≡C or CH=CH group; and

$\mathbf{R^{14}}$ is selected from (1-6C)alkoxy-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, hydroxyl-(1-6C)alkyl or from a group of formula:

$$(CH_2)_x\text{-}N(R^c)\text{-}C(O)\text{-}NR^aR^b$$

wherein x is 0, 1, 2 or 3, R^c is hydrogen or (1-6C)alkyl and R^a and R^b are each independently selected from hydrogen and (1-6C)alkyl or R^a and R^b together with the nitrogen to which they are attached form morpholino,

or from a group of the formula :

$$-X^7-Q^5$$

wherein X^7 is a direct bond and Q^5 is aryl, heteroaryl, heterocyclyl, heterocyclyl-(1-6C)alkyl, or heterocyclyloxy-(1-6C)alkyl,

and wherein any CH, CH_2 or CH_3 group within a R^{14} substituent optionally bears on each said CH, CH_2 or CH_3 group a substituent selected from (1-6C)alkoxy, carbamoyl, N-(1-6C)alkylcarbamoyl or a group of the formula :

$$-X^8-Q^6$$

wherein X^8 is a direct bond or O and Q^6 is (3-7C)cycloalkyl or heterocyclyl

and wherein any heterocyclyl group within a substituent on R^{14} optionally bears 1 oxo substituent;

or a pharmaceutically acceptable acid addition salt thereof.

Claim 9 (**currently amended**): The ~~A~~ quinazoline derivative of the Formula I according to claim 1 wherein

Z is NH

m is 2 and the **first** $\mathbf{R^1}$ group is at the 5-position and is selected from isopropoxy, tetrahydro-2H-pyran-4-yloxy and the **second** $\mathbf{R^1}$ group is at the 7- position and is selected from methoxy, 3-morpholin-4-ylpropoxy, 3-(4-acetylpiperazin-1-yl)propoxy, 3-(4-formylacetylpiperazin-1-yl)propoxy and 3-(3-oxo-4-methyl-piperazin-1-yl)propyoxy

n is 1 and $\mathbf{R^3}$ group is located at the 5-position of the 1,3-benzodioxol-4-yl group and is chloro;

$\mathbf{Z^2}$ is a C≡C or CH=CH group; and

$\mathbf{R^{14}}$ is selected from methoxymethyl, 2-methoxyethyl, methoxyisopropyl and pyridin-2-yl,

or a pharmaceutically acceptable acid addition salt thereof.

Claim 10 (**currently amended**): The ~~A~~ quinazoline derivative of the Formula 1 according to claim 1 and selected from

N-[5-chloro-7-(3-methoxyprop-1-ynyl)-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

N-[5-chloro-7-(4-methoxybut-1-yn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

N-[5-chloro-7-(3-ethoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

N-[5-chloro-7-(3-isopropoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

N-{5-chloro-7-[3-(cyclopropylmethoxy)prop-1-yn-1-yl]-1,3-benzodioxol-4-yl}-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

(1-{3-[(4-{[5-chloro-7-(4-methoxybut-1-yn-1-yl)-1,3-benzodioxol-4-yl]amino}-6-methoxyquinazolin-7-yl)oxy]propyl}piperidin-4-yl)methanol,

N'-[3-(6-chloro-7-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino}-1,3-benzodioxol-4-yl)prop-2-yn-1-yl]-*N*,*N*-dimethylurea,

7-{3-[bis(2-methoxyethyl)amino]propoxy}-*N*-[5-chloro-7-(4-methoxybut-1-yn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxyquinazolin-4-amine,

4-{3-[(4-{[5-chloro-7-(4-methoxybut-1-yn-1-yl)-1,3-benzodioxol-4-yl]amino}-6-methoxyquinazolin-7-yl)oxy]propyl}piperazine-1-carbaldehyde,

N-[5-chloro-7-(4-methoxybut-1-yn-1-yl)-1,3-benzodioxol-4-yl]-7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-6-methoxyquinazolin-4-amine,

N-[5-chloro-7-(4-methoxybut-1-yn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxy-7-[3-(4-methoxypiperidin-1-yl)propoxy]quinazolin-4-amine,

4-{3-[(4-{[5-chloro-7-(4-methoxybut-1-yn-1-yl)-1,3-benzodioxol-4-yl]amino}-6-methoxyquinazolin-7-yl)oxy]propyl}-1-methylpiperazin-2-one,

4-{3-[(4-{[5-chloro-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]amino}-6-methoxyquinazolin-7-yl)oxy]propyl}-1-methylpiperazin-2-one,

N'-{3-[6-chloro-7-({6-methoxy-7-[3-(4-methyl-3-oxopiperazin-1-yl)propoxy]quinazolin-4-yl}amino)-1,3-benzodioxol-4-yl]prop-2-yn-1-yl}-*N*,*N*-dimethylurea,

1-{3-[(4-{[5-chloro-7-(pyridin-2-ylethynyl)-1,3-benzodioxol-4-yl]amino}-6-methoxyquinazolin-7-yl)oxy]propyl}-4-methylpiperazin-2-one,

N'-{3-[6-chloro-7-({7-[3-(cis-2,6-dimethylmorpholin-4-yl)propoxy]-6-methoxyquinazolin-4-yl}amino)-1,3-benzodioxol-4-yl]prop-2-yn-1-yl}-*N*,*N*-dimethylurea,

N-[5-chloro-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxy-7-(4-morpholin-4-ylbutoxy)quinazolin-4-amine,

N-[5-chloro-7-(pyridin-2-ylethynyl)-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

N-[5-chloro-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]-7-{3-(cis-2,6-dimethylmorpholin-4-yl]propoxy}-6-methoxyquinazolin-4-amine,

N-[5-chloro-7-[(tetrahydrofuran-3-ylmethoxy)methyl]-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

N-[5-chloro-7-{[(1,3-dioxolan-2-yl)methoxy]methyl}-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

N-[5-chloro-7-[(tetrahydrofuran-3-yloxy)methyl]-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

N-[5-chloro-7-(pyridin-3-ylethynyl) -1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

N-[5-chloro-7-(1H-pyrazol-4-ylethynyl)-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

4-{3-[(4-{[5-chloro-7-(3-methoxybut-1-yn-1-yl)-1,3-benzodioxol-4-yl]amino}-6-methoxyquinazolin-7-yl)oxy]propyl}-1-methylpiperazin-2-one,

N-[5-bromo-7-(3-methoxybut-1-yn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

4-{3-[(4-{[5-bromo-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]amino}-6-methoxyquinazolin-7-yl)oxy]propyl}-1-methylpiperazin-2-one,

N-[5-chloro-7-(pyridin-2-ylethynyl)-1,3-benzodioxol-4-yl]-7-[3-(cis-2,6dimethylmorpholin-4-yl]propoxy)]-6-methoxyquinazolin-4-amine,

4-{3-[(4-{[5-Chloro-7-(3-isopropoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]amino}-6-methoxyquinazolin-7-yl)oxy]propyl}-1-methylpiperazin-2-one,

N-[5-chloro-7-(1H-pyrazol-5-ylethynyl)-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

4-{3-[(4-{[5-chloro-7-(pyridin-2-ylethynyl)-1,3-benzodioxol-4-yl]amino}-6-methoxyquinazolin-7-yl)oxy]propyl}-1-methylpiperazin-2-one,

N-[5-chloro-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxy-7-[3-(4-hydroxypiperidin-1-yl)propoxy]-quinazolin-4-amine,

((2*R*)-1-{3-[(4-{[5-chloro-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]amino}-6-methoxyquinazolin-7-yl)oxy]propyl}pyrrolidin-2-yl)methanol,

4-{3-[(4-{[5-chloro-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]amino}-6-methoxyquinazolin-7-yl)oxy]propyl}piperazin-2-one,

N-[5-chloro-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]-7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-6-methoxyquinazolin-4-amine,

N-[5-chloro-7-(4-methoxybut-1-yn-1-yl)-1,3-benzodioxol-4-yl]-7-(3-morpholin-4-ylpropoxy)-5-(tetrahydro-2*H*-pyran-4-yloxy)quinazolin-4-amine,

N-[5-chloro-7-(4-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]-7-(3-morpholin-4-ylpropoxy)-5-isopropoxyquinazolin-4-amine,

7-[3-(4-acetylpiperazin-1-yl)propoxy]-*N*-[5-chloro-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]-5-isopropoxyquinazolin-4-amine,

N-[5-chloro-7-(pyridin-2-ylethynyl)-1,3-benzodioxol-4-yl]-5-isopropoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

4-{3-[(4-{[5-chloro-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]amino}-5-isopropoxyquinazolin-7-yl)oxy]propyl}piperazine-1-carbaldehyde,

4-{3-[(4-{[5-chloro-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]amino}-5-isopropoxyquinazolin-7-yl)oxy]propyl}-1-methylpiperazin-2-one,

N-[5-chloro-7-(3-methoxybut-1-yn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine,

N-[5-bromo-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-amine and

N-[5-chloro-7-(3-methoxyprop-1-yn-1-yl)-1,3-benzodioxol-4-yl]-7-[3-(dimethylamino)propoxy]-6-methoxyquinazolin-4-amine,

or a pharmaceutically acceptable acid addition salt thereof.

Claim 11 (**currently amended**): A process for the preparation of a quinazoline derivative of the Formula I or a pharmaceutically-acceptable salt thereof , according to claim 1 which comprises:-

(a) the reaction of a quinazoline of the Formula II



II

wherein L is a displaceable group and m and R^1 have any of the meanings defined in claim 1 except that any functional group optionally is protected ~~if necessary~~, with a compound of the Formula III



III

wherein Z is O, S, or N(R^2) and n, R^3, R^2, Z^2 and R^{14} have any of the meanings defined in claim 1 except that any functional group optionally is protected ~~if necessary~~, whereafter any protecting group that is present is removed ~~by conventional means~~;

(b) for the production of those compounds of the Formula I wherein at least one R^1 group is a group of the formula

$$Q^1\text{-}X^1\text{-}$$

wherein Q^1 is ~~an aryl-(1-6C)alkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heteroaryl-(1-6C)alkyl or~~ a heterocyclyl-(1-6C)alkyl group ~~or an optionally substituted alkyl group~~ and X^1 is an oxygen atom, the coupling~~, conveniently in the presence of a suitable dehydrating agent,~~ of a quinazoline of the Formula V



V

wherein m, R^1, Z, n, R^3, Z^2 and R^{14} have any of the meanings defined in claim 1, except that any functional group optionally is protected ~~if necessary~~, with an appropriate alcohol of the formula Q^1-OH wherein any functional group optionally is protected ~~if necessary~~, whereafter any protecting group that is present is removed ~~by conventional means~~;

(c) for the production of those compounds of the Formula I wherein R^1 is an amino-substituted (1-6C)alkoxy group ~~(such as 2-homopiperidin-1-ylethoxy or 3-dimethylaminopropoxy)~~, the reaction of a compound of the Formula I wherein R^1 is a halogeno-substituted (1-6C)alkoxy group with a heterocyclyl compound or an appropriate amine;

(d) for the production of those compounds of the Formula I wherein an R^1 group contains a (1-6C)alkoxy or substituted (1-6C)alkoxy group or a (1-6C)alkylamino or substituted (1-6C)alkylamino group, the alkylation of a quinazoline derivative of the Formula I wherein the R^1 group contains a hydroxy group or a primary or secondary amino group as appropriate;

(e) for the production of those compounds of the Formula I wherein Z is a SO or SO_2 group, wherein an ~~R^1 or~~ R^3 substituent is a (1-6C)alkylsulphinyl or (1-6C)alkylsulphonyl group or wherein an ~~R^1~~, R^3 ~~or R^{14}~~-substituent contains a SO or SO_2 group, the oxidation of a compound of the Formula I wherein Z is a S group or wherein an ~~R^1 or~~ R^3 substituent is a (1-6C)alkylthio group or wherein an ~~R^1~~ R^3 ~~or R^{14}~~-substituent contains a S group as appropriate;

(f) the reaction of a compound of the Formula VI



VI

wherein L is a displaceable group as defined hereinbefore and m, R^1, Z, n and R^3 have any of the meanings defined in claim hereinbefore except that any functional group optionally is protected ~~if necessary~~, with a compound of the Formula VII



VII

wherein Z^2 is a C≡C or $C(R^{13})=C(R^{13})$ group and R^{13} and R^{14} have any of the meanings defined in claim1 except that any functional group optionally is protected ~~if necessary~~, whereafter any protecting group that is present is removed ~~by conventional means~~;

~~(g) for the production of a compound of the Formula I wherein R^{14} is a carboxy group, the cleavage of a compound of the Formula I wherein R^{14} is a (1-6C)alkoxycarbonyl group;~~

(g) ~~(h)~~ the reaction of a compound of the Formula I wherein R^{14} is a carboxy group with an appropriate amine to form a further compound of the Formula I wherein R^{14} is a carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl or heterocyclylcarbonylamino group; or

(h) ~~(i)~~ a coupling reaction of a compound of the Formula VIII



VIII

wherein m, R^1, Z, n and R^3 have any of the meanings defined in claim 1 except that any functional group optionally is protected ~~if necessary~~, with a compound of the Formula IX



IX

wherein L is a displaceable group and R^{14} has any of the meanings defined in claim 1 except that any functional group optionally is protected ~~if necessary~~, whereafter any protecting group that is present is removed ~~by conventional means~~;

and optionally forming ~~when~~ a pharmaceutically-acceptable salt of a quinazoline derivative of Formula I ~~is required it may be obtained using a conventional procedure~~.

Claim 12 (**currently amended**): A pharmaceutical composition which comprises a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof as defined in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

Claims 13-16 (**cancelled**).

Claim 17 (**new**): A method for the treatment of solid tumour disease in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as claimed in claim 1.